Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


09.04.2018

2 BJU Int
3 BMC Cancer
1 Br J Radiol
1 Clin Cancer Res
3 J Clin Oncol
1 Lancet Oncol
2 Nat Rev Urol
3 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. LAING R, Uribe J, Uribe-Lewis S, Money-Kyrle J, et al
    LDR brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    BJU Int. 2018 Apr 1. doi: 10.1111/bju.14223.
    PubMed     Text format     Abstract available

  2. EBBINGE M, Berglund A, Varenhorst E, Hedlund PO, et al
    Clinical and Prognostic Significance of Changes in Haemoglobin Level During One Year of Androgen Deprivation Treatment for Hormone-Naive Bone Metastatic Prostate Cancer.
    BJU Int. 2018 Apr 2. doi: 10.1111/bju.14227.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. DAWSON JK, Dorff TB, Todd Schroeder E, Lane CJ, et al
    Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    BMC Cancer. 2018;18:368.
    PubMed     Text format     Abstract available

  4. TOSCO L, Laenen A, Gevaert T, Salmon I, et al
    Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    BMC Cancer. 2018;18:354.
    PubMed     Text format     Abstract available

  5. BOWLER E, Porazinski S, Uzor S, Thibault P, et al
    Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
    BMC Cancer. 2018;18:355.
    PubMed     Text format     Abstract available


    Br J Radiol

  6. DUFFTON A, Sadozye A, Devlin L, MacLeod N, et al
    Safety and feasibility of prostate stereotactic ablative radiotherapy using multi-modality imaging and flattening filter free.
    Br J Radiol. 2018 Jan 17:20170625. doi: 10.1259/bjr.20170625.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  7. GORDEVICIUS J, Krisciunas A, Groot DE, Yip SM, et al
    Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0101.
    PubMed     Text format     Abstract available


    J Clin Oncol

  8. MORRIS MJ, Rumble RB, Basch E, Hotte SJ, et al
    Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2018 Apr 2:JCO2018780619. doi: 10.1200/JCO.2018.78.0619.
    PubMed     Text format     Abstract available

  9. SARTOR O
    Curing More Prostate Cancer: Thinking Through the Options.
    J Clin Oncol. 2018 Apr 6:JCO2018784835. doi: 10.1200/JCO.2018.78.4835.
    PubMed     Text format    

  10. HUSSAIN M, Tangen CM, Thompson IM Jr, Swanson GP, et al
    Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
    J Clin Oncol. 2018 Apr 6:JCO2017764126. doi: 10.1200/JCO.2017.76.4126.
    PubMed     Text format     Abstract available


    Lancet Oncol

  11. THE LANCET ONCOLOGY
    New interventions offer prostate cancer hope.
    Lancet Oncol. 2018;19:427.
    PubMed     Text format    


    Nat Rev Urol

  12. THOMA C
    Prostate cancer: Quality of life during chemohormonal therapy.
    Nat Rev Urol. 2018 Apr 5. pii: nrurol.2018.44. doi: 10.1038/nrurol.2018.
    PubMed     Text format    

  13. THOMA C
    Prostate cancer: Validating radiographic progression-free survival.
    Nat Rev Urol. 2018 Apr 5. pii: nrurol.2018.46. doi: 10.1038/nrurol.2018.
    PubMed     Text format    


    Prostate

  14. PREISSER F, Bandini M, Graefen M, Tilki D, et al
    Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23521.
    PubMed     Text format    

  15. BRATT O
    RE: Preissner F, et al. extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23520.
    PubMed     Text format    

  16. PRENCIPE M, Fabre A, Murphy TB, Vargyas E, et al
    Role of serum response factor expression in prostate cancer biochemical recurrence.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23516.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: